Hi Joe Nothing has changed We are in the Non Ambulant space with DMD and Limb girdle R2 Sarepta has limb girdle but not R2 science If we only have DMD in Europe it’s still a $5 stock Sarepta can’t market their Dmd drugs in Europe FDA has set a prcedent. ( no need to show efficacy and safety data ) So we just have to replicate the end points pUL -2 and we should be able to market our drugs in Europe and USA..
